Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | NUMARZU-001 |
Synonyms | |
Therapy Description |
Limited information is currently available on NUMARZU-001, a putative cell therapy comprised of PD-1 (PDCD1)-positive tumor infiltrating lymphocytes (Apr 2023). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NUMARZU-001 | NUMARZU001|NUMARZU 001 | Limited information is currently available on NUMARZU-001, a putative cell therapy comprised of PD-1 (PDCD1)-positive tumor infiltrating lymphocytes (Apr 2023). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05451784 | Phase Ib/II | NUMARZU-001 | Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS (TILS001) | Recruiting | ESP | 0 |